Key Takeaways:
BeOne Medicines Ltd. said its BTK inhibitor BRUKINSA (zanubrutinib) plus rituximab reduced the risk of disease progression or death by 43% versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma, meeting the primary endpoint of the Phase 3 MANGROVE study.
"The results demonstrate for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the treatment paradigm globally," Amit Agarwal, M.D., Ph.D., Chief Medical Officer of Hematology at BeOne Medicines, said.
The hazard ratio of 0.57 (95% CI, 0.43-0.76; p<0.0001) means patients receiving the BRUKINSA combination had a 43% lower risk of progression or death compared with those on standard chemoimmunotherapy. The trial enrolled 510 patients across 176 sites worldwide, making it the first global Phase 3 study to evaluate a BTK inhibitor-based chemotherapy-free regimen against standard chemoimmunotherapy in frontline MCL. Overall survival data were immature at the time of analysis, though a strong trend favoring the BRUKINSA arm was observed.
Mantle cell lymphoma is a rare, aggressive B-cell non-Hodgkin lymphoma that predominantly affects older adults, who often have comorbidities limiting their tolerance to chemotherapy. The MANGROVE regimen also eliminated the need for rituximab maintenance, sparing patients approximately two years of infusions. The safety profile of BRUKINSA plus rituximab was consistent with the known safety of both medicines, with no new signals identified.
Chemo-free approach addresses unmet need in frontline MCL
Standard frontline care for MCL has long relied on chemoimmunotherapy such as bendamustine plus rituximab, which carries burdens including myelosuppression, prolonged immune suppression, and cumulative toxicity. Prior efforts to improve outcomes with BTK inhibitors focused on adding them to chemotherapy rather than replacing it. MANGROVE is the first Phase 3 trial to advance a chemotherapy-free, rituximab maintenance-free approach in first-line MCL.
BRUKINSA is a next-generation BTK inhibitor designed for complete and sustained target inhibition. It is the first and only BTK inhibitor to demonstrate progression-free survival superiority over another BTK inhibitor in a Phase 3 study. Approved in more than 80 markets, the drug has been used to treat over 290,000 patients worldwide.
Regulatory submissions planned for second half of 2026
BeOne Medicines plans to submit global regulatory filings in the second half of 2026. Full results from MANGROVE, including detailed efficacy and safety data, will be presented at an upcoming medical meeting.
The positive readout strengthens BRUKINSA's position as a foundational therapy across B-cell malignancies and opens a potential new frontline standard in MCL. Investors will watch for the full data presentation and regulatory decisions, which could expand the drug's addressable patient population beyond the relapsed or refractory setting.
This article is for informational purposes only and does not constitute investment advice.
